Lin Y - Search Results

1

The application of targeted RNA sequencing for the analysis of fusion genes, gene mutations, IKZF1 intragenic deletion, and CRLF2 overexpression in acute lymphoblastic leukemia.

Zhang Z, Jing Y, Chen B, Zhang H, Liu T, Dong S, Zhang L, Yan X, Yang S, Chen L, Lin Y, Ru K. Zhang Z, et al. Among authors: lin y. Int J Lab Hematol. 2024 Mar 29. doi: 10.1111/ijlh.14269. Online ahead of print. Int J Lab Hematol. 2024. PMID: 38553845

2

Increased drug efflux along with midkine gene high expression in childhood B-lineage acute lymphoblastic leukemia cells.

Hu R, Yan Y, Li Q, Lin Y, Jin W, Li H, Lu Y, Pang T. Hu R, et al. Among authors: lin y. Int J Hematol. 2010 Jul;92(1):105-10. doi: 10.1007/s12185-010-0613-x. Epub 2010 Jun 11. Int J Hematol. 2010. PMID: 20544404

3

[Diagnostic features of myeloproliferative neoplasms].

Lin Y, Liu E, Ru K. Lin Y, et al. Zhonghua Bing Li Xue Za Zhi. 2015 Feb;44(2):81-3. Zhonghua Bing Li Xue Za Zhi. 2015. PMID: 25916636 Chinese. No abstract available.

4

The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.

Lin Y, Liu E, Sun Q, Ma J, Li Q, Cao Z, Wang J, Jia Y, Zhang H, Song Z, Ai X, Shi L, Feng X, Li C, Wang J, Ru K. Lin Y, et al. Am J Clin Pathol. 2015 Jul;144(1):165-71. doi: 10.1309/AJCPALP51XDIXDDV. Am J Clin Pathol. 2015. PMID: 26071474

5

SIRT2 mediates multidrug resistance in acute myelogenous leukemia cells via ERK1/2 signaling pathway.

Xu H, Li Y, Chen L, Wang C, Wang Q, Zhang H, Lin Y, Li Q, Pang T. Xu H, et al. Among authors: lin y. Int J Oncol. 2016 Feb;48(2):613-23. doi: 10.3892/ijo.2015.3275. Epub 2015 Dec 7. Int J Oncol. 2016. PMID: 26647771

6

[Molecular diagnosis of hematologic neoplasms].

Lin Y, Ru K. Lin Y, et al. Zhonghua Bing Li Xue Za Zhi. 2015 Aug;44(8):612-4. Zhonghua Bing Li Xue Za Zhi. 2015. PMID: 26705191 Chinese. No abstract available.

7

[Comprehensive diagnosis of hematologic neoplasms].

Liu E, Lin Y, Wang H, Li C, Ru K. Liu E, et al. Among authors: lin y. Zhonghua Xue Ye Xue Za Zhi. 2016 Jan;37(1):83-6. doi: 10.3760/cma.j.issn.0253-2727.2016.01.019. Zhonghua Xue Ye Xue Za Zhi. 2016. PMID: 26876263 Free PMC article. Chinese. No abstract available.

8

[Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].

Qin T, Xu Z, Zhang Y, Lin Y, Ru K, Fang L, Zhang H, Pan L, Hu N, Qu S, Wang J, Xing R, Xiao Z. Qin T, et al. Among authors: lin y. Zhonghua Xue Ye Xue Za Zhi. 2016 Feb;37(2):94-9. doi: 10.3760/cma.j.issn.0253-2727.2016.02.002. Zhonghua Xue Ye Xue Za Zhi. 2016. PMID: 27014976 Free PMC article. Chinese.

9

[Co-occurrence of t(8;21)(q22;q22) and t(9;22)(q34;q11) in a case with chronic myelogenous leukemia].

Gong J, Li J, Gai Y, Tian X, Feng X, Lin Y, Liu E, Ru K. Gong J, et al. Among authors: lin y. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2019 Mar 10;36(3):253-256. doi: 10.3760/cma.j.issn.1003-9406.2019.03.015. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2019. PMID: 30835358 Chinese.

10

A novel SERPINC1 frameshift mutation in two antithrombin deficiency families.

Zhang D, Sun B, Zhang X, Li H, Lin Y, Qin L, Chen L, Zhang L, Ru K, Yang R. Zhang D, et al. Among authors: lin y. Int J Lab Hematol. 2020 Apr;42(2):e48-e51. doi: 10.1111/ijlh.13097. Epub 2019 Aug 23. Int J Lab Hematol. 2020. PMID: 31441586 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

49,338 results

Search Page